Cellectis SA (CLLS)

Cellectis SA Stock Analysis & Ratings


CLLS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.30 - $15.50
Previous Close$3.81
Average Volume (3M)140.88K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-1.5
Next EarningsNov 15, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)-2.49
Shares Outstanding45,490,810
Standard Deviation0.18
10 Day Avg. Volume82,284
30 Day Avg. Volume140,878
P/B Ratio0.72
P/S Ratio6.08
P/CF Ratio266.40
P/FCF Ratio-1.20
Total Debt$85.36M
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside91.99% Upside
Rating ConsensusHold
Number of Analyst Covering4



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $2.30 and its highest was $15.50 in the past 12 months.
    What is Cellectis SA’s market cap?
    Currently, no data Available
    What is Cellectis SA’s price target?
    The average price target for Cellectis SA is $7.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $11.00 ,the lowest forecast is $2.00. The average price target represents 91.99% Increase from the current price of $3.995.
      What do analysts say about Cellectis SA?
      Cellectis SA’s analyst rating consensus is a ‘Hold. This is based on the ratings of 4 Wall Streets Analysts.
        When is Cellectis SA’s upcoming earnings report date?
        Cellectis SA’s upcoming earnings report date is Nov 15, 2022 which is in 92 days.
          How were Cellectis SA’s earnings last quarter?
          Cellectis SA released its earnings results on Aug 04, 2022. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.514 by $0.094.
            Is Cellectis SA overvalued?
            According to Wall Street analysts Cellectis SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Cellectis SA pay dividends?
              Cellectis SA does not currently pay dividends.
              What is Cellectis SA’s EPS estimate?
              Cellectis SA’s EPS estimate is -$0.38.
                How many shares outstanding does Cellectis SA have?
                Cellectis SA has 45,475,310 shares outstanding.
                  What happened to Cellectis SA’s price movement after its last earnings report?
                  Cellectis SA reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.514. Following the earnings report the stock price went up 10.897%.
                    Which hedge fund is a major shareholder of Cellectis SA?
                    Among the largest hedge funds holding Cellectis SA’s share is Bpifrance SA. It holds Cellectis SA’s shares valued at 1M.


                      Cellectis SA Stock Analysis

                      Smart ScoreNeutral
                      The Cellectis SA stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Cellectis SA

                      Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

                      Similar Stocks
                      Price & Change
                      Bluebird Bio
                      Intellia Therapeutics

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis